NASDAQ · GRI
GRI Bio, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GRI: Nov 13, 2026
GRI Bio, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.84. The reported EPS for the same quarter last year was $-35.85.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.84 | $-0.75 | $-0.93 | 2 |
| Dec 2026 | $-0.83 | $-0.74 | $-0.91 | 2 |
| Mar 2027 | $-0.98 | $-0.98 | $-0.98 | 1 |
| Jun 2027 | $-0.96 | $-0.96 | $-0.96 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Quiver Quantitative · Fintel · RTTNews- Quiver Quantitative · Jul 1, 8:50 AM EDTGRI Bio, Inc. Completes Patient Enrollment in Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis, Interim Results Show Safety and TolerabilityGRI Bio announced positive interim safety results for GRI-0621 in a Phase 2a study for IPF, with data expected Q3 2025.
- Quiver Quantitative · Jun 26, 8:13 AM EDTGRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary FibrosisIDMC recommends continuing Phase 2a study of GRI-0621 for IPF, showing safety and tolerability in initial patients.
- Quiver Quantitative · May 22, 8:12 AM EDTGRI Bio Reports Promising Preclinical Data for GRI-0621 in Treatment of Pulmonary Fibrosis at 2025 ATS ConferenceGRI Bio presented promising data on GRI-0621's anti-inflammatory and anti-fibrotic effects for idiopathic pulmonary fibrosis at ATS 2025.
- Quiver Quantitative · May 16, 9:21 AM EDTGRI Bio, Inc. CEO Marc Hertz to Participate in Live Webcast Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025GRI Bio's CEO Marc Hertz to discuss innovative NKT cell therapies at A.G.P.'s Annual Healthcare Company Showcase on May 21.
- Quiver Quantitative · May 15, 8:44 AM EDTGRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis TreatmentGRI Bio reports positive interim results for GRI-0621 in IPF treatment; patient enrollment nearing completion, cash runway extended to Q3 2025.
- Quiver Quantitative · Mar 18, 9:13 AM EDTGRI Bio, Inc. CEO Marc Hertz Discusses Advancements in NKT Cell Modulators for IPF in Recent Virtual Investor SegmentGRI Bio's CEO discusses the company's innovative therapies for autoimmune diseases in a virtual investor segment.
- Quiver Quantitative · Mar 17, 8:15 AM EDTGRI Bio, Inc. Anticipates Key Phase 2a Data Readouts for GRI-0621 in 2025 While Securing Cash Runway for OperationsGRI Bio anticipates interim and topline data for GRI-0621 in 2025, aiming to address IPF treatment gaps.
- Quiver Quantitative · Mar 11, 8:42 AM EDTGRI Bio, Inc. Regains Compliance with Nasdaq Minimum Bid Price RuleGRI Bio, Inc. announced it has regained compliance with Nasdaq’s minimum bid price rule.
- Quiver Quantitative · Feb 19, 9:12 AM ESTGRI Bio, Inc. Highlights Key Investment Reasons at Virtual Investor ConferenceGRI Bio presented its investment potential at a virtual conference, showcasing its NKT cell modulators for autoimmune diseases.
- Quiver Quantitative · Dec 23, 9:12 AM ESTGRI Bio, Inc. Advances Global Patent Strategy with European Patent Grant for NKT Cell Modulator InnovationGRI Bio advances its NKT cell modulators with a new European patent, enhancing its intellectual property portfolio.
- Fintel · Feb 13, 4:32 PM ESTLind Global Fund II Cuts Stake in Vallon Pharmaceuticals (VLON)Fintel reports that Lind Global Fund II has filed a 13G/A form with the SEC disclosing ownership of 0.01MM shares of Vallon Pharmaceuticals Inc. (VLON). This represents 0.1% of the company.
- RTTNews · Feb 13, 7:47 AM ESTPre-market Movers: GTHX, VLON, ZIVO, ACGN, OCUL…(RTTNews) – The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.35 A.M. ET).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for GRI Bio, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.